Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

被引：0
|
作者：
Albliwi, Moath [1 ]
Mustafa, Moaath K. [2 ]
Nurse, Daniel P. [3 ]
El-Asmar, Jessica [2 ]
Batah, Heya [1 ]
Abuamsha, Hasan [1 ]
Rauf, Asaad [4 ]
Hanna, John [1 ]
Abu-Farsakh, Yomna [2 ]
Bawwab, Ameed [1 ]
Zabor, Emily C. [5 ]
Bedelu, Yohana B. [5 ]
Chen, Mark Jinan
Nakitandwe, Joy [6 ]
Jain, Akriti G. [2 ]
Gerds, Aaron T.
Balderman, Sophia [2 ]
Molina, John C. [7 ]
Mukherjee, Sudipto [2 ]
Advani, Anjali S. [2 ]
Carraway, Hetty E. [2 ]
机构：
[1] Cleveland Clin, Dept Internal Med, Cleveland, OH USA
[2] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH USA
[3] Cleveland Clin, Dept Internal Med, University Hts, OH USA
[4] Cleveland Clin, Internal Med, Cleveland, OH USA
[5] Cleveland Clin, Dept Quantitat Hlth Sci, Taussig Canc Inst, Cleveland, OH USA
[6] Cleveland Clin, Dept Pathol & Lab Med, Diagnost Inst, Cleveland, OH USA
[7] NCI, Pediat Oncol Branch, Shaker Hts, OH USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-205776
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1473 / 1474
页数：2
相关论文
共 50 条
  • [1] Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
    Mustafa Ali, Moaath K.
    Corley, Elizabeth M.
    Alharthy, Hanan
    Kline, Kathryn A. F.
    Law, Jennie Y.
    Lee, Seung Tae
    Niyongere, Sandrine
    Duong, Vu H.
    Emadi, Ashkan
    Baer, Maria R.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
    Weiss, Julian J.
    Yates, Samuel J.
    Badar, Talha
    Patel, Anand Ashwin
    Winer, Eric S.
    Litzow, Mark R.
    Cheng, Wei
    Lin, Chenyu
    Shallis, Rory M.
    BLOOD, 2024, 144 : 1489 - 1490
  • [3] Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification
    Wan, Chao-Ling
    Liu, Yu-Qing
    Liu, Fang-Tong
    Huang, Yuan-Hong
    Cao, Han-Yu
    Huang, Si-Man
    Tan, Kai-Wen
    Ge, Shuai-Shuai
    Wang, Miao
    Liu, Mei-Jing
    Wang, Zi-Hao
    Li, Zheng
    Xue, Sheng-Li
    Dai, Hai-Ping
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [4] Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
    Shen, Jingyi
    Shan, Meng
    Chu, Mengqian
    Cai, Yiming
    Rui, Jingwen
    Chen, Suning
    Wu, Depei
    Xu, Yang
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [5] Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Berton, Guillaume
    Schaefer, Eva J.
    Zeidan, Amer M.
    Goldberg, Aaron
    Stein, Eytan
    Marcucci, Guido
    Bystrom, Rebecca P.
    Lindsley, R. Coleman
    Chen, Evan C.
    Ramos, Jorge
    Stein, Anthony
    Pullarkat, Vinod
    Aldoss, Ibrahim
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Garciaz, Sylvain
    Ball, Brian
    Stahl, Maximilian
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1640 - 1643
  • [6] Intensive Induction Chemotherapy Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Schaefer, Eva Johanna
    Zeidan, Amer M.
    Goldberg, Aaron D.
    Stein, Eytan M.
    Marcucci, Guido
    Lindsley, Coleman
    Chen, Evan C.
    Ramos, Jorge
    Stein, Anthony Selwyn
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Ball, Brian J.
    Stahl, Maximilian
    BLOOD, 2023, 142
  • [7] Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
    Lachowiez, Curtis A.
    Reville, Patrick K.
    Kantarjian, Hagop
    Jabbour, Elias
    Borthakur, Gautam
    Daver, Naval
    Loghavi, Sanam
    Furudate, Ken
    Xiao, Lianchun
    Pierce, Sherry
    Short, Nicholas J.
    Maiti, Abhishek
    Yilmaz, Musa
    Sasaki, Koji
    Takahashi, Koichi
    Konopleva, Marina
    Pemmaraju, Naveen
    Popat, Uday
    Shpall, Elizabeth
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    DiNardo, Courtney D.
    Kadia, Tapan M.
    LANCET HAEMATOLOGY, 2022, 9 (05): : E350 - E360
  • [8] Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia
    Lim, Matthew J.
    Agha, Aya
    Im, Annie
    Raptis, Anastasios
    Hou, Jing Z.
    Boyiadzis, Michael
    Sehgal, Alison R.
    Redner, Robert L.
    Dorritie, Kathleen
    Marks, Stanley S.
    Agha, Mounzer E.
    Lim, Seah H.
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (02) : 495 - 497
  • [9] Hematologic Predictors of Outcomes in Patients Undergoing Intensive Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
    Arain, Saad
    Shah, Eshana
    Yavuz, Betul Gok
    Stettner, Sarah
    Calip, Gregory Sampang
    Khan, Irum
    Patel, Pritesh
    Quigley, John G.
    BLOOD, 2020, 136
  • [10] Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study
    Wang, Miao
    Cao, Han-Yu
    Tan, Kai-Wen
    Qiu, Qiao-Cheng
    Huang, Yuan-Hong
    Ge, Shuai-shuai
    Wang, Zi-Hao
    Chen, Jia
    Tang, Xiao-Wen
    Wu, De-Pei
    Xue, Sheng-Li
    Li, Zheng
    Dai, Hai-Ping
    BLOOD CANCER JOURNAL, 2023, 13 (01)
12345